What Montair-LC Treats: Main Uses and Benefits

The primary therapeutic role of Montair-LC is to provide supportive and sustained relief from challenging allergic symptoms, applied across domains where additional symptomatic support is needed. The primary therapeutic purpose is aligned with conditions presenting with systemic or localized discomfort and inflammatory or irritative processes.

The medicine is relevant for managing symptom patterns of perennial and seasonal allergic rhinitis, chronic skin reactions like idiopathic urticaria, and offering adjunctive support for mild to moderate allergic asthma and exercise-induced bronchoconstriction. This supportive approach is relevant in contexts involving heightened systemic burden.

This medication is commonly used to help with distressing symptom patterns, including nasal congestion, runny nose, sneezing, itching of the nose and eyes, and recurrent itchy welts on the skin. The therapeutic benefit helps improve day-to-day comfort during periods of heightened symptoms, which assists with maintaining comfort. The medicine helps address symptom clusters that may become intense or disruptive, offering symptomatic relief that helps patients cope more steadily with difficult episodes.

---

Quick Fact: Use in Combined Symptom Patterns

Montair-LC is often used when groups of symptoms—such as nasal congestion and skin itching—appear suddenly or fluctuate, providing support that helps ease the overall symptom burden.

Regulatory References

1. FDA Verification Portal (Philippines) on Montelukast + Levocetirizine

Who can and cannot use Montair-LC?

This information reflects the official eligibility and non-eligibility rules documented in authoritative governmental regulatory sources (e.g., FDA, EMA).

Populations Who Must Not Use (Contraindicated):

The medicine is formally contraindicated for patients who have a known hypersensitivity or allergy to montelukast, levocetirizine, cetirizine, or any other component in the formulation. Use is also strictly prohibited in patients with End-Stage Renal Disease (eGFR below 15 mL/ min) requiring dialysis, and in children aged 6 months to 11 years with any degree of impaired kidney function.

Furthermore, use is contraindicated in patients with certain hereditary digestive disorders, specifically rare problems of galactose intolerance, Lapp lactase deficiency, or glucose-galactose malabsorption.

Age and Specific Condition Rules:

The standard tablet formulation is indicated for use in adults and adolescents aged 15 years and older. Use is generally not recommended in women who are pregnant or breastfeeding. Caution is advised in patients with predisposing factors for urinary retention (such as prostatic hyperplasia) due to the levocetirizine component.

Interactions with other medicines and products

Official regulatory information for Montair-LC details specific pharmacokinetic and pharmacodynamic interactions stemming from its two components. The Montelukast component’s systemic exposure is significantly affected by co-administered medicinal products that interact with cytochrome P450 enzymes.

Pharmacokinetic and Exposure Alterations

Interaction Type	Interacting Substance	Official Regulatory Description of Effect
Exposure Increase (Inhibition)	Gemfibrozil	Increases Montelukast systemic exposure (AUC) by approximately 4.4-fold.
Exposure Decrease (Induction)	Rifampicin, Phenobarbital	Significantly reduces Montelukast systemic exposure.

Pharmacodynamic and Substance Interactions

The Levocetirizine component carries a risk for additive effects when combined with substances that affect the central nervous system. Co-administration with alcohol or other CNS depressants is documented to result in an additive impairment of alertness and psychomotor performance. While no changes in the total absorbed amount occur, taking the medicine with food is officially stated to decrease the rate of Levocetirizine absorption. For patients with documented aspirin sensitivity, regulatory documents caution against the continued use of aspirin or other NSAIDs, as these agents can trigger symptoms like asthma.

Official studies found no clinically important pharmacokinetic interactions between Montelukast and medicinal products such as Warfarin, Theophylline, Digoxin, or Oral Contraceptives.

Population-Specific Notes

The clearance of the Levocetirizine component is officially reduced in individuals with impaired renal function, leading to increased systemic drug exposure.

How Montair-LC Works

Montair-LC modulates the body’s inflammatory response by using two distinct and complementary antagonistic mechanisms. This dual-pathway approach provides complementary mechanistic engagement against the key chemical mediators released during allergic hypersensitivity.

---

Targeting the Histamine Pathway ( H1 Receptor Blockade)

The levocetirizine component is associated with rapid receptor occupancy by acting as a highly selective antagonist of the peripheral Histamine H1 receptor. This action prevents histamine from binding and activating its receptor, thereby stabilizing microvascular permeability and reducing sensory nerve stimulation, which modulates the physiological response leading to tissue edema.

---

Modulating the Leukotriene Pathway ( CysLT1 Receptor Antagonism)

The montelukast component targets the sustained aspect of inflammation by competitively antagonizing the Cysteinyl Leukotriene CysLT1 receptor. Blocking this receptor inhibits the signaling cascade mediated by leukotrienes, which are key mediators of airway smooth muscle contraction and the migration of pro-inflammatory cells like eosinophils into tissues.

---

Synergistic Dual Pathway Antagonism

These two separate mechanistic domains—blocking H1 signaling and blocking CysLT1 signaling—act in complementary fashion against two distinct phases of the inflammatory cascade. This simultaneous dual-pathway inhibition facilitates a comprehensive modulation of both the rapid, acute tissue responses and the chronic, underlying cellular inflammatory processes.

How to Use Montair-LC

This section describes the administration principles and general usage patterns for the fixed-dose combination of Levocetirizine 5 mg and Montelukast 10 mg.

Administration Route and Dosing

Montair-LC is administered via the oral route as a film-coated tablet. The standard labeled dose for adults and adolescents aged 15 years and older is one tablet of the 10 mg/5 mg strength taken once daily (OD). This single daily tablet constitutes the maximum dose recommended within the fixed-combination regimen. The tablet must be swallowed whole with liquid and should not be chewed, broken, or crushed.

Timing and Contextual Use

Administration may occur with or without food. To align with the activity profile of the components, the dose is generally recommended to be taken in the evening or at night. The treatment pattern is determined by the condition being addressed: the medicine may be used as continuous, long-term therapy for chronic conditions, or on an intermittent basis for temporary issues such as seasonal rhinitis, where administration may cease upon symptom resolution.

Population and Procedural Adjustments

Specific use constraints and adjustments apply to certain populations. The 10 mg/5 mg tablet strength is not intended for use in patients below 15 years of age. Furthermore, dose frequency is adjusted for patients with moderate to severe renal impairment to account for the altered elimination of the levocetirizine component, such as a reduced frequency of one dose every two days. If a dose is missed, the next scheduled dose should be taken at the usual time; a double dose should not be taken to compensate.

Montair-LC: Recent Clinical Evidence

The Montair-LC product is a fixed-dose combination of montelukast (a leukotriene receptor antagonist) and levocetirizine (a second-generation antihistamine). Clinical research has primarily focused on evaluating whether this dual-action treatment is associated with enhanced relief for symptoms of allergic rhinitis (AR), especially in patients who also experience coexisting asthma.

---

Efficacy in Allergic Rhinitis (AR)

Recent systematic reviews and meta-analyses, which pool data from multiple randomized controlled trials (RCTs), have investigated the use of this combination therapy for AR.

• Symptom Control: Studies have explored whether combining montelukast with levocetirizine is associated with greater improvement in AR symptoms (such as sneezing, runny nose, and nasal congestion) compared to using either component medication alone (monotherapy). The evidence generally suggests that the combination may offer increased symptom control, particularly for daytime symptoms and nasal congestion, which may be less effectively addressed by antihistamine monotherapy.

• Quality of Life: The trials also investigated whether the combination was associated with changes in patient-reported rhinoconjunctivitis-related quality of life (RQLQ) scores.

---

Findings in Combined Allergic Rhinitis and Asthma

Clinical rationale supports using this combination to target both histamine- and leukotriene-mediated inflammation, which are central to both AR and asthma. Research in populations with the combined allergic rhinitis and asthma syndrome (CARAS) has examined whether the dual therapy provides comprehensive relief that may be lacking with single-drug approaches.

Safety and Tolerability

Across multiple studies, the safety profile of the combined treatment has been consistently reviewed. The incidence of treatment-emergent adverse events (AEs) was generally observed to be similar between the combination therapy and monotherapy groups. Common reported AEs often reflect the known profiles of the individual components, such as drowsiness or fatigue associated with the antihistamine component.

Common questions about Montair-LC (FAQ)

---

Q: What is the role of levocetirizine in Montair-LC?

The levocetirizine component of the combination works as an H1-receptor antagonist. This means it acts to prevent histamine, a key chemical released during an allergic reaction, from binding to its receptors. This mechanism is associated with relief of acute allergy symptoms.

---

Q: What is the role of montelukast in Montair-LC?

The montelukast component is classified as a Leukotriene Receptor Antagonist (LTRA). Its role is to block cysteinyl leukotriene receptors involved in inflammation and bronchoconstriction, which are sustained aspects of allergic conditions.

---

Q: Why is Montair-LC a combination medicine instead of two separate tablets?

The medicine is formulated as a fixed-dose combination to provide what official sources describe as a dual-pathway inhibition. This strategy targets both histamine- and leukotriene-mediated inflammation. Studies and official information indicate this dual action may facilitate a comprehensive modulation of inflammatory processes, particularly for symptoms like nasal congestion.

---

Q: Is Montair-LC considered a habit-forming or addictive medicine?

Official regulatory documents classify the product based on its pharmacological class ( H1 Antihistamine and LTRA). The active ingredients in Montair-LC are not classified or reported in official regulatory texts as controlled or habit-forming substances.

---

Q: What is the risk profile of serious side effects associated with Montair-LC?

Specific warnings note that the montelukast component has been associated with neuropsychiatric events. These events have included reports of changes in mood, depression, aggression, and suicidal thoughts and behavior. Rarely, conditions such as systemic eosinophilia, sometimes consistent with Churg-Strauss syndrome, have also been reported in official documents.

---

Q: How soon might a person notice relief of allergy symptoms after starting Montair-LC?

Official pharmacokinetic information indicates that the levocetirizine component is rapidly absorbed by the body. Peak levels of this component are typically reached approximately one hour after the tablet is taken orally.

---

Q: Is Montair-LC intended for long-term or short-term treatment?

According to the official product information, the medicine may be used for both long-term and short-term therapy. It may be used as continuous, long-term therapy for chronic conditions, or on an intermittent basis for temporary issues such as seasonal rhinitis, where administration may stop once symptoms resolve.

---

Q: Are there known interactions between Montair-LC and common pain relievers like ibuprofen?

Clinical studies examining the montelukast component have not shown evidence of clinically important adverse interactions when it was used concomitantly with a wide range of commonly prescribed drugs. This includes non-steroidal anti-inflammatory agents (NSAIDs).

---

Q: Does Montair-LC interact with other types of anti-allergic medicines?

The levocetirizine component may have an additive effect when co-administered with other central nervous system depressants. Official documents state this may result in increased impairment of alertness and psychomotor performance. This is a possibility with certain other anti-allergic agents that may have sedative properties.

---

Q: Are there known interactions between Montair-LC and antiepileptic medicines like Phenytoin?

Official information for the montelukast component indicates that its systemic exposure is significantly affected by co-administered medicinal products that interact with CYP450 enzymes. Montelukast exposure is known to be reduced by CYP450 inducers, and caution is advised when using the medicine with inducers like Phenytoin.

---

Q: Is Montair-LC generally appropriate for use in adolescents (over 15 years old)?

The standard tablet strength (10 mg/5 mg) of the combination is officially indicated for use in adults and adolescents aged 15 years and older. The eligibility for use is defined by this age limit in the regulatory documents for the product.

---

Q: What is the safety classification of Montair-LC for pregnant women?

Official product information states that there are no adequate and well-controlled studies of the active components in pregnant women. Therefore, the use of the combination is not recommended during pregnancy.

---

Q: Is Montair-LC recommended for women who are breastfeeding?

Regulatory documents indicate that it is not known whether both Montelukast or Levocetirizine are excreted in human breast milk. Due to this lack of data, the use of the combination is not recommended for women who are breastfeeding.

---

Q: Are there contraindications for Montair-LC use in individuals with liver problems?

The montelukast component is primarily cleared from the body through bile. Official sources advise that caution is necessary when prescribing this combination to patients with impaired hepatic (liver) function, although no dosage adjustment is specified for mild-to-moderate impairment.

---

Q: Does taking Montair-LC affect a person's ability to operate machinery?

Official guidance cautions individuals against engaging in hazardous activities requiring complete mental alertness and motor co-ordination, such as operating machinery or driving. This caution is advised until the person knows how the medicine affects them.

---

Q: Does Montair-LC contain phenylalanine?

The medicine is formally contraindicated in patients with certain hereditary digestive disorders, such as rare problems of galactose intolerance, Lapp lactase deficiency, or glucose-galactose malabsorption. This information relates to potential excipients (inactive ingredients) within the formulation.

How to Store and Dispose of Montair-LC

The storage and disposal of Montair-LC tablets are governed by specific regulatory requirements to ensure product stability and safety. The official guidelines mandate that the product must be stored at room temperature, specifically below 30 C.

Storage Conditions

Item	Requirement
Temperature	Below 30 C
Protection	Protect from light and moisture
Packaging	Store in the original container
Child Safety	Keep out of the sight and reach of children

Disposal

The medicine should not be used past the expiry date printed on the packaging. Any unused or expired Montair-LC tablets must be disposed of in accordance with local regulations for pharmaceutical waste, which typically prevents disposal through household trash or wastewater.